Compare AMETEK, Inc. (AME) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs Illumina, Inc. — how do they compare? AMETEK, Inc. trades at $255.78 (market cap $58.76B), while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: AMETEK, Inc. is far larger — about 2× Illumina, Inc.'s market cap, and AMETEK, Inc. pays a 0.53% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| AME | ILMN | |
|---|---|---|
Market Cap | $58.76B | $29.12B |
Sector | Industrials | Health |
52-Week High | $256.30 | $205.10 |
52-Week Low | $179.28 | $91.00 |
Enterprise Value | $60.30B | $30.48B |
Dividend Yield | 0.53% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
